HACKENSACK, N.J., April 4, 2013 (GLOBE NEWSWIRE) -- Champions Oncology, Inc. (OTC:CSBR) is pleased to announce that it will be presenting six posters on its Champions TumorGraft™ models and Translational Oncology Solutions at the 2013 American Association of Cancer Research (AACR) Annual Meeting being held April 6 - 10 in Washington, DC. Champions will also be exhibiting at the event at Booth #1008.
The posters represent Champions' investment in research and development to expand the value of TumorGraft technology for drug development. The work to be presented will include advancements in targeted TumorGraft model development, characterization of relevant cancer pathways, as well as collaborative work on cancer cachexia models and the utility of next generation DNA sequencing in personalized cancer treatment.
Joel Ackerman, Champions Oncology's CEO, stated, "We are very excited to be presenting several key advancements in our TumorGraft technology platform at the 2013 AACR Annual Meeting. We also look forward to discussing the application of these advancements with the cancer research community during the event."
The posters can be viewed during the following times during the AACR Annual Meeting. For questions, reprints of the posters, or to arrange a meeting with Champions staff during the event, please contact us here.
| Poster Title | Abstract # | Date | Time | Section # | Board # |
| Integrated next generation sequencing and patient-derived xenografts to personalized cancer treatment | 2205 | Monday, April 8, 2013 | 1:00 PM-5:00 PM | 42 | 14 |
| Development of an androgen-dependent prostate Champions TumorGraft™ cancer model | 2783 | Tuesday, April 9, 2013 | 8:00 AM - 12:00 PM | 19 | 21 |
| Characterization of spontaneous in vivo cachexia models in Champions TumorGraft™ models | 2792 | Tuesday, April 9, 2013 | 8:00 AM - 12:00 PM | 19 | 20 |
| Champions TumorGraft™ models represent oncology clinical trial populations | 2779 | Tuesday, April 9, 2013 | 8:00 AM - 12:00 PM | 19 | 26 |
| Champions TumorGraft™ models possess PIK3CA mutations - A great tool to explore the PI3K/AKT pathway | 2774 | Tuesday, April 9, 2013 | 8:00 AM - 12:00 PM | 19 | 9 |
| Functional profiling of Champions TumorGraft™ models from metastatic melanoma patients | 3498 | Tuesday, April 9, 2013 | 1:00 PM - 5:00 PM | 2 | 16 |
About Champions Oncology, Inc.
Champions Oncology, Inc. is engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs. The Company's TumorGraft Technology Platform is a novel approach to personalizing cancer care based upon the implantation of primary human tumors in immune deficient mice followed by propagation of the resulting engraftments, or TumorGrafts, in a manner that preserves the biological characteristics of the original human tumor in order to determine the efficacy of a treatment regimen. The Company uses this technology in conjunction with related services to offer solutions for two customer groups: Personalized Oncology Solutions, in which results help guide the development of personalized treatment plans, and Translational Oncology Solutions, in which pharmaceutical and biotechnology companies seeking personalized approaches to drug development can lower the cost and increase the speed of developing new drugs. TumorGrafts are procured through agreements with a number of institutions in the U.S. and overseas as well as through its Personalized Oncology Solutions business.
This press release may contain "forward-looking statements" (within the meaning of the Private Securities Litigation Act of 1995) that inherently involve risk and uncertainties. Champions Oncology generally uses words such as "believe," "may," "could," "will," "intend," "expect," "anticipate," "plan," and similar expressions to identify forward-looking statements. One should not place undue reliance on these forward-looking statements. The Company's actual results could differ materially from those anticipated in the forward-looking statements for many unforeseen factors. See Champions Oncology's Form 10-K for the fiscal year ended April 30, 2012 for a discussion of such risks, uncertainties and other factors. Although the Company believes the expectations reflected in the forward-looking statements are reasonable, they relate only to events as of the date on which the statements are made, and Champions Oncology's future results, levels of activity, performance or achievements may not meet these expectations. The Company does not intend to update any of the forward-looking statements after the date of this press release to conform these statements to actual results or to changes in Champions Oncology's expectations, except as required by law.